Viridian Therapeutics Inc
VRDNHealthcare|Biotechnology|USA
$19.75
-0.46 (-2.28%)
Tangible Book
$4.92
Clinical Trials (8)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06812325 A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) | Thyroid Eye Disease (TED) | P3 | Active | 320 | RCT, Double-blind | VRDN-003, Placebo |
| NCT06625411 An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) | Thyroid Eye Disease | P3 | Active | 132 | RCT, Double-blind | VRDN-003, Placebo |
| NCT06625398 An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED) | Thyroid Eye Disease | P3 | Active | 204 | RCT, Double-blind | VRDN-003, Placebo |
| NCT07155668 A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) | Thyroid Eye Disease | P3 | Completed | 87 | RCT, Open-label | VRDN-003 |
| NCT05176639 A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid Eye Disease (TED) ( THRIVE ) | Thyroid Eye Disease | P3 | Completed | 113 | RCT, Double-blind | VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo |
| NCT06384547 A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) | Thyroid Eye Disease | P3 | Completed | 231 | RCT, Double-blind | VRDN-001 10 mg/kg, VRDN-001 3 mg/kg |
| NCT06021054 An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2) | Thyroid Eye Disease | P3 | Completed | 188 | RCT, Double-blind | Veligrotug (VRDN-001), Placebo |
| NCT06179875 An Open-label Study (OLE) for Non-responders of VRDN-001-101 (NCT05176639) and VRDN-001-301 (NCT06021054) | Thyroid Eye Disease | P3 | Completed | 143 | Open-label | Veligrotug |